Abbvie Inc
NYSE:ABBV

Watchlist Manager
Abbvie Inc Logo
Abbvie Inc
NYSE:ABBV
Watchlist
Price: 175.58 USD 2.37% Market Closed
Market Cap: 310.3B USD
Have any thoughts about
Abbvie Inc?
Write Note

Abbvie Inc
Total Receivables

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Abbvie Inc
Total Receivables Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Receivables CAGR 3Y CAGR 5Y CAGR 10Y
Abbvie Inc
NYSE:ABBV
Total Receivables
$11.5B
CAGR 3-Years
7%
CAGR 5-Years
16%
CAGR 10-Years
11%
Gilead Sciences Inc
NASDAQ:GILD
Total Receivables
$4.6B
CAGR 3-Years
0%
CAGR 5-Years
7%
CAGR 10-Years
5%
Amgen Inc
NASDAQ:AMGN
Total Receivables
$7.3B
CAGR 3-Years
15%
CAGR 5-Years
15%
CAGR 10-Years
12%
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Total Receivables
$353.9m
CAGR 3-Years
36%
CAGR 5-Years
49%
CAGR 10-Years
97%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Total Receivables
$1.8B
CAGR 3-Years
17%
CAGR 5-Years
32%
CAGR 10-Years
31%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Total Receivables
$6.1B
CAGR 3-Years
4%
CAGR 5-Years
18%
CAGR 10-Years
21%
No Stocks Found

Abbvie Inc
Glance View

Market Cap
310.3B USD
Industry
Biotechnology
Economic Moat
Wide

AbbVie Inc., a leader in the pharmaceutical industry, emerged from its parent company Abbott Laboratories in 2013, with a mission centered around addressing some of the world’s most complex and serious diseases. At its core, AbbVie is a research-driven entity that leverages scientific innovation to develop advanced therapies. With a robust pipeline, the company focuses on key therapeutic areas like immunology, oncology, neuroscience, eye care, virology, and women's health. It has developed a diversified portfolio designed to tackle challenging health issues. The company devotes significant resources to research and development, fostering a culture that celebrates scientific discovery as a pathway to improving patient lives worldwide. Revenue generation for AbbVie is deeply intertwined with its treatment offerings, particularly its lineup of blockbuster drugs. The flagship product, Humira, an anti-inflammatory medication, has consistently stood as one of the top-selling drugs globally. Despite facing patent expirations for Humira, AbbVie has strategically navigated this challenge through its robust product pipeline, which includes promising medicines like Skyrizi and Rinvoq in immunology. The company also expanded its revenue potential significantly with the acquisition of Allergan in 2020, adding Botox and other products in aesthetics and eye care to its portfolio. The calculated diversification of revenue streams ensures AbbVie maintains a competitive edge, securing its position as a formidable player in the pharmaceutical industry.

ABBV Intrinsic Value
150.06 USD
Overvaluation 15%
Intrinsic Value
Price

See Also

What is Abbvie Inc's Total Receivables?
Total Receivables
11.5B USD

Based on the financial report for Sep 30, 2024, Abbvie Inc's Total Receivables amounts to 11.5B USD.

What is Abbvie Inc's Total Receivables growth rate?
Total Receivables CAGR 10Y
11%

Over the last year, the Total Receivables growth was 1%. The average annual Total Receivables growth rates for Abbvie Inc have been 7% over the past three years , 16% over the past five years , and 11% over the past ten years .

Back to Top